News

In The News ADVI’s Vice President, Dr. Michael Kolodziej, talked to The American Journal of Managed Care about the side effects of first-gen BTK inhibitors
In The News ADVI’s Lindsay Bealor Greenleaf sat down with CNBC to share her thoughts on the White House’s recent executive orders on drug pricing reform, and how the proposal could have unintended consequences leading to increased Medicare spending
In The News ADVI Health CEO, Marc Samuels, spoke with AIS Health about the Trump administration’s drug pricing executive orders, and why they might face industry backlash
In The News ADVI’s Vice President, Lindsay Bealor Greenleaf, explained to Modern Healthcare about the implications of CMS’ new proposed rule for Medicaid
In The News ADVI Vice President, Dr. Michael Kolodziej, recently shared his thoughts on how commercial insurers and hospitals are being impacted by the Covid-19 pandemic with The Cancer Letter
In The News ADVI’s Director, Becca Davison, connected with Fox Business to discuss what she’d like to see from lawmakers when it comes to health policy
In The News ADVI’s Lindsay Bealor Greenleaf talks to Politico about the new Medicaid proposed rule
In The News ADVI’s Lindsay Bealor Greenleaf sat down with the Daily Caller to discuss some of the problems that this proposal would have posed for patients
In The News “Insulins are typically heavily rebated products, and Part D beneficiaries’ out-of-pocket costs are based on a pre-rebated list price,” ADVI VP Lindsay Bealor Greenleaf explained to BioWorld about the costs of insulin